69,587 Shares in Celcuity, Inc. $CELC Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new position in Celcuity, Inc., purchasing 69,587 shares valued at approximately $704,000, representing about 0.18% ownership of the company.
• Institutional investors and hedge funds collectively own 63.33% of Celcuity's shares, indicating strong interest from larger investment entities.
• Celcuity reported a quarterly loss of ($1.04) EPS, missing analysts' estimates, with a consensus target price of $56.50 and a consensus rating of "Buy" from investment analysts.

Nuveen LLC purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 69,587 shares of the company's stock, valued at approximately $704,000. Nuveen LLC owned about 0.18% of Celcuity at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CELC. Gagnon Securities LLC increased its stake in shares of Celcuity by 3.5% during the first quarter. Gagnon Securities LLC now owns 54,310 shares of the company's stock worth $549,000 after acquiring an additional 1,831 shares during the period. Perkins Capital Management Inc. acquired a new stake in shares of Celcuity in the first quarter worth $115,000. Bank of New York Mellon Corp boosted its stake in shares of Celcuity by 7.2% in the first quarter. Bank of New York Mellon Corp now owns 68,766 shares of the company's stock valued at $695,000 after purchasing an additional 4,641 shares during the period. Focus Financial Network Inc. bought a new position in shares of Celcuity during the first quarter worth about $108,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Celcuity by 17.2% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 168,740 shares of the company's stock worth $1,706,000 after buying an additional 24,708 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Price Performance

Shares of CELC traded up $6.39 during mid-day trading on Monday, hitting $62.08. 751,060 shares of the stock were exchanged, compared to its average volume of 603,453. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $61.40. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The firm has a 50-day moving average of $34.32 and a two-hundred day moving average of $18.92. The company has a market cap of $2.63 billion, a PE ratio of -17.79 and a beta of 0.72.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). On average, equities analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

CELC has been the subject of a number of analyst reports. HC Wainwright lifted their target price on shares of Celcuity from $50.00 to $66.00 and gave the company a "buy" rating in a research note on Monday, August 18th. Stifel Nicolaus assumed coverage on shares of Celcuity in a report on Tuesday, July 1st. They set a "buy" rating and a $30.00 price objective on the stock. Needham & Company LLC reduced their price objective on shares of Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Finally, Leerink Partners lifted their price objective on shares of Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, July 28th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $56.50.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the transaction, the director directly owned 125,000 shares in the company, valued at $5,497,500. The trade was a 44.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 15.78% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.